Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan.
Hiromi HagiwaraTakafumi NakayamaMasahide OkiShigeru KusumotoHidekatsu FukutaTakeshi KamiyaKoichi IkutaShinsuke IidaPublished in: Cancer medicine (2023)
Complication of renal impairment and prior lenalidomide treatment could be risk factors influencing OS and TTNT during carfilzomib treatment.
Keyphrases